Liquid Biopsy Test Commercially Launched for Detection of Prostate Cancer

The Cchek Prostate Cancer Confirmation test—which utilizes artificial intelligence, flow cytometry, and liquid-biopsy technology to detect prostate cancer—has been commercially launched, according to Anixa Biosciences, Inc., developer of the test. Once it becomes available, this test will reduce the need for expensive and invasive biopsy procedures to diagnose patients with prostate cancer in…

Read the full article here

Related Articles